Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 2:6:JGO.2016.008144.
doi: 10.1200/JGO.2016.008144. eCollection 2020.

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

Alexandra S Rashedi  1 Saskia F de Roo  2 Lauren M Ataman  1 Maxwell E Edmonds  1 Adelino Amaral Silva  3 Anibal Scarella  4 Anna Horbaczewska  5 Antoinette Anazodo  6 Ayse Arvas  7 Bruno Ramalho de Carvalho  8 Cassio Sartorio  9 Catharina C M Beerendonk  2 Cesar Diaz-Garcia  10 Chang Suk Suh  11 Cláudia Melo  12 Claus Yding Andersen  13 Eduardo Motta  14 Ellen M Greenblatt  15 Ellen Van Moer  16 Elnaz Zand  17 Fernando M Reis  14 Flor Sánchez  18 Guillermo Terrado  19 Jhenifer K Rodrigues  14 João Marcos de Meneses E Silva  20 Johan Smitz  16 Jose Medrano  21 Jung Ryeol Lee  11 Katharina Winkler-Crepaz  22 Kristin Smith  1 Lígia Helena Ferreira Melo E Silva  20 Ludwig Wildt  22 Mahmoud Salama  23 María Del Mar Andrés  21 Maria T Bourlon  24 Mario Vega  25 Maurício Barbour Chehin  26 Michel De Vos  27 Mohamed Khrouf  28 Nao Suzuki  29 Osama Azmy  23 Paula Fontoura  30 Paulo Henrique Almeida Campos-Junior  31 Peter Mallmann  32 Ricardo Azambuja  33 Ricardo M Marinho  34 Richard A Anderson  35 Robert Jach  5 Roberto de A Antunes  36 Rod Mitchell  35 Rouhollah Fathi  17 Satish Kumar Adiga  37 Seido Takae  29 Seok Hyun Kim  11 Sergio Romero  18 Silvana Chedid Grieco  38 Talya Shaulov  39 Tatsuro Furui  40 Teresa Almeida-Santos  12 Willianne Nelen  2 Yasmin Jayasinghe  41 Yodo Sugishita  29 Teresa K Woodruff  1
Affiliations

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

Alexandra S Rashedi et al. JCO Glob Oncol. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] JCO Glob Oncol. 2022 Mar;8:e2100412. doi: 10.1200/GO.21.00412. JCO Glob Oncol. 2022. PMID: 35275733 Free PMC article. No abstract available.

Abstract

Purpose: Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale.

Methods: Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health-funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services.

Results: Sixty-three responses were received (response rate, 25%), and 40 were analyzed from oncofertility centers in 28 countries. Thirty of 40 survey results (75%) showed that formal referral processes and psychological care are provided to patients at the majority of sites. Fourteen of 23 respondents (61%) stated that some fertility preservation services are not offered because of cultural and legal barriers. The growth of oncofertility and its capacity to improve the lives of cancer survivors around the globe relies on concentrated efforts to increase awareness, promote collaboration, share best practices, and advocate for research funding.

Conclusion: This survey reveals global and regional successes and challenges and provides insight into what is needed to advance the field and make the discussion of fertility preservation and endocrine health a standard component of the cancer treatment plan. As the field of oncofertility continues to develop around the globe, regular assessment of both international and regional barriers to quality care must continue to guide process improvements.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc. Alexandra S. RashediEmployment: Cigna (I) Stock or Other Ownership: Cigna (I)Antoinette AnazodoResearch Funding: Merck SeronoCassio SartorioEmployment: Vida Centro de Fertilidade Leadership: Vida Centro de Fertilidade Stock or Other Ownership: Vida Centro de FertilidadeCatharina C.M. BeerendonkTravel, Accommodations, Expenses: GoodlifeEllen M. GreenblattConsulting or Advisory Role: Ferring Pharmaceuticals, EMD Serono Travel, Accommodations, Expenses: EMD SeronoFernando M. ReisHonoraria: Politec Saúde (I) Consulting or Advisory Role: Politec Saúde (I) Speakers’ Bureau: UCB (I) Travel, Accommodations, Expenses: Abbott Laboratories (I)Johan SmitzSpeakers’ Bureau: Ferring Pharmaceuticals Travel, Accommodations, Expenses: Ferring PharmaceuticalsMaria T. BourlonLeadership: Medivation, Astellas Pharma Honoraria: Medivation, Astellas Pharma Speakers’ Bureau: Asofarma Research Funding: Bristol-Myers Squibb Travel, Accommodations, Expenses: Janssen PharmaceuticalsMichel De VosHonoraria: Cook Medical Research Funding: Cook MedicalRichard A. AndersonConsulting or Advisory Role: Roche, HRA Pharma, NeRe Pharmaceuticals Speakers’ Bureau: Roche, Beckman Coulter, IBSA Institut Biochimque Research Funding: Ferring Pharmaceuticals Travel, Accommodations, Expenses: IBSA Institut BiochimqueRoberto de A. AntunesConsulting or Advisory Role: Merck Serono Speakers’ Bureau: Merck Serono Travel, Accommodations, Expenses: Merck Serono, MSDTeresa Almeida-SantosConsulting or Advisory Role: Merck, MSD Research Funding: MerckTeresa K. WoodruffResearch Funding: Ferring Pharmaceuticals (Inst) No other potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
Fertility preservation services offered to patients at survey respondent organizations. (A) Pediatric patients. (B) Adolescent patients. (C) Adult patients.

References

    1. Letourneau JM; Ebbel EE Katz PP et al. : Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 118:1710-1717, 2012 - PMC - PubMed
    1. De Vos M, Smitz J, Woodruff TK: Fertility preservation in women with cancer. Lancet 384:1302-1310, 2014 - PMC - PubMed
    1. Khrouf M, Bouyahia M, Berjeb K, et al: Perurethral transvesical route for oocyte retrieval: An old technique for a new indication. Fertil Steril 106:e129, 2016 (suppl 3)
    1. Rashedi AS, de Roo SF, Ataman LM, et al: Survey of third-party parenting options associated with fertility preservation available to patients with cancer around the globe. J Glob Oncol doi: 10.1200/JGO.2017.009944. - DOI - PMC - PubMed
    1. Cunningham CT, Quan H, Hemmelgarn B, et al. : Exploring physician specialist response rates to Web-based surveys. BMC Med Res Methodol 15:32, 2015 - PMC - PubMed

Publication types